Study #SWOGS1602
SWOGS1602: A PHASE III RANDOMIZED TRIAL TO EVALUATE THE INFLUENCE OF BCG STRAIN DIFFERENCES AND T CELL PRIMING WITH INTRADERMAL BCG BEFORE INTRAVESICAL THERAPY FOR BCG-NAIVE HIGH-GRADE NON-MUSCLE INVASIVE BLADDER CANCER
MD Anderson Study Status
Not Accepting
Treatment Agent
BCG Solution, BCG Tokyo-172 Strain Solution, BCG Tokyo-172 Strain Vaccine
Description
This randomized phase III trial studies Tokyo-172 strain bacillus Calmette-Guerin (BCG) solution with or without a vaccination using Tokyo-172 strain BCG to see how well it works compared with TICE BCG solution in treating patients with bladder cancer that has not spread to muscle. BCG is a non-infectious bacteria that when instilled into the bladder may stimulate the immune system to fight bladder cancer. Giving different versions of BCG with vaccine therapy may prevent bladder cancer from returning.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Stage 0 Bladder Urothelial Carcinoma, Stage 0is Bladder Urothelial Carcinoma, Stage I Bladder Urothelial Carcinoma
Study phase:
Phase III
Physician name:
Ashish Kamat
Department:
Urology
For general questions about clinical trials:
1-855-982-0789
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.